Kaleido Biosciences, Inc. (KLDO): Price and Financial Metrics


Kaleido Biosciences, Inc. (KLDO): $7.07

-0.44 (-5.86%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add KLDO to Watchlist
Sign Up

Industry: Biotech


Ranked

of 491

in industry

KLDO Stock Summary

  • Kaleido Biosciences Inc's stock had its IPO on February 28, 2019, making it an older stock than just 4.36% of US equities in our set.
  • With a price/sales ratio of 307.94, Kaleido Biosciences Inc has a higher such ratio than 98.1% of stocks in our set.
  • As for revenue growth, note that KLDO's revenue has grown 290% over the past 12 months; that beats the revenue growth of 97.74% of US companies in our set.
  • Stocks that are quantitatively similar to KLDO, based on their financial statements, market capitalization, and price volatility, are EVGN, AGIO, SRRA, TBPH, and RARE.
  • Visit KLDO's SEC page to see the company's official filings. To visit the company's web site, go to www.kaleido.com.

KLDO Stock Price Chart Interactive Chart >

Price chart for KLDO

KLDO Price/Volume Stats

Current price $7.07 52-week high $20.50
Prev. close $7.51 52-week low $5.04
Day low $6.91 Volume 581,200
Day high $7.55 Avg. volume 299,082
50-day MA $10.14 Dividend yield N/A
200-day MA $8.59 Market Cap 300.24M

Kaleido Biosciences, Inc. (KLDO) Company Bio


Kaleido Biosciences, Inc. is a healthcare company, which focuses on leveraging the potential of the microbiome organ to treat disease and improve human health. The company was founded by Geoffrey von Maltzahn and Noubar B. Afeyan in 2015 and is headquartered in Lexington, MA.


KLDO Latest News Stream


Event/Time News Detail
Loading, please wait...

KLDO Latest Social Stream


Loading social stream, please wait...

View Full KLDO Social Stream

Latest KLDO News From Around the Web

Below are the latest news stories about Kaleido Biosciences Inc that investors may wish to consider to help them evaluate KLDO as an investment opportunity.

Biotech company Kaleido develops oral therapy for COVID-19

Dan Menichella, Kaleido CEO, joins Yahoo Finance’s Anjalee Khemlani, Alexis Christoforous and Kristin Myers to discuss the utilization of oral therapeutic KB109 for COVID-19 and emerging variants.

Yahoo | April 6, 2021

CytoDyn (CYDY) Files New Protocol With FDA for COVID-19 Study

CytoDyn (CYDY) submits a new protocol with the regulatory body in the United States to study a higher dose of leronlimab for severely-infected COVID-19 patients.

Yahoo | April 1, 2021

Kaleido (KLDO) Reports Positive Results from COVID-19 Study

Kaleido (KLDO) announces impressive results from a study on KB109 in patients with mild-to-moderate COVID-19.

Yahoo | March 25, 2021

Kaleido Biosciences Stock Is Trading Higher On Positive KB109 Data In COVID-19 Study

Kaleido Biosciences Inc (NASDAQ: KLDO) reported positive results from a non-IND study of KB109 in patients with mild-to-moderate COVID-19. KB109 demonstrated an overall favorable safety and tolerability profile with no unexpected treatment-related adverse events. The treatment reduced healthcare utilization, as measured by the total number of hospitalizations, emergency room visits, and urgent care visits by approximately 62% among patients with one or more comorbidity and about 51% overall. For patients with one or more comorbidity, KB109 reduced the median time to resolving the 13 overall COVID-19 symptoms from 30 to 21 days. The study also demonstrated a significant reduction in recovery time for patients aged 45 and older or with one or more comorbidity who received KB109 plus self-...

Yahoo | March 24, 2021

Kaleido Biosciences says oral drug cuts COVID-19 recovery time, hospitalizations

Kaleido Biosciences said on Wednesday its experimental oral treatment cut recovery time as well as hospitalizations and emergency room visits in patients with mild to moderate COVID-19, in an early trial. The treatment, KB109, reduced the total number of hospitalizations, emergency room visits, and urgent care visits by 51% in a study of 350 patients, and by 62% among patients with one or more co-morbidities, the company said. Kaleido said gut microbes can produce molecules that are believed to modulate such responses.

Yahoo | March 24, 2021

Read More 'KLDO' Stories Here

KLDO Price Returns

1-mo -29.51%
3-mo -41.08%
6-mo -26.89%
1-year N/A
3-year N/A
5-year N/A
YTD -22.31%
2020 81.27%
2019 N/A
2018 N/A
2017 N/A
2016 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 0.9585 seconds.